Maternal blood tests that look at the alphafetoprotein levels can suggest the presence of neural tube defects like spina bifida, a deformity of the spinal column, and anencephaly, an absence of all or part of the brain and skull. This test can also be a marker for Down syndrome. More invasive tests include amniocentesis and chorionic villi sampling. These allow the direct examination of fetal chromosomes in order to detect genetic abnormalities. These tests are more accurate, but they also carry more risk for the unborn child. The decision to undertake any form of prenatal testing must weigh the risks against the potential therapeutic benefits derived from the information provided by such procedures.
While prenatal testing offers the opportunity to correct some abnormalities or to prepare to adjust to others, it is unfortunately often utilized to screen for diseases and abort unborn children who are deemed defective. In 2007, the American College of Obstetrics and Gynecology (ACOG) changed their recommendations for prenatal screening from offering tests to pregnant women over age 35 to offering them to all pregnant women. Their rationale was that while women over age 35 had the greatest risk for conceiving a child with Down syndrome, most children with Down syndrome were born to women under the age of 35. The expanded screening would allow for these cases to be detected prenatally.
Currently, 92% of all children with Down syndrome in the United States are aborted…